Aquestive Therapeutics, Inc. Income Statement

Income Statement Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 66.92M67.43M52.61M4.00M50.83M47.68M50.58M1.01M
Gross Profit 47.10M46.44M32.25M-8.96M35.84M28.29M29.75M-16.86M
Operating items
Research & Development 22.13M23.11M20.57M19.89M17.05M17.48M13.10M20.28M
Selling, General & Administrative 25.08M72.27M64.34M55.89M53.48M52.88M31.75M50.18M
Other Operating Expenses 19.82M20.99M20.36M12.96M14.99M19.39M20.83M17.87M
Operating Expenses 67.03M116.37M105.28M88.74M85.51M89.75M65.69M88.33M
Operating Income -0.11M-48.93M-52.67M-42.89M-34.68M-42.07M-15.10M-30.77M
EBIT -0.11M-48.93M-52.67M-42.89M-34.68M-42.07M-15.10M-30.77M
Non-operating items
Interest & Investment Income 0.55M0.64M0.13M0.42M0.10M16.32M3.44M
Other Non Operating Income -4.90M-13.82M-1.38M
Net income details
EBT -8.94M-61.38M-66.25M-55.78M-70.54M-54.41M-7.62M-44.15M
Tax Provisions 0.24M-0.01M
Profit After Tax -8.94M-61.38M-66.25M-55.78M-70.54M-54.41M-7.87M-44.14M
Income from Continuing Operations -8.94M-61.38M-66.25M-55.78M-70.54M-54.41M-7.87M-44.14M
Consolidated Net Income -8.94M-61.38M-66.25M-55.78M-70.54M-54.41M-7.87M-44.14M
Income towards Parent Company -8.94M-61.38M-66.25M-55.78M-70.54M-54.41M-7.87M-44.14M
Preferred Dividend Payments 2.48M
Net Income towards Common Stockholders -11.42M-61.38M-66.25M-55.78M-70.54M-54.41M-7.87M-44.14M
Additional items
EPS (Basic) -0.48-2.96-2.61-1.66-1.85-1.12-0.13-0.51
EPS (Weighted Average and Diluted) -1.66-1.85-1.12-0.13-0.51
Shares Outstanding (Weighted Average) 24.00M24.94M25.04M33.62M40.16M54.16M66.77M91.18M
Shares Outstanding (Diluted Average) 33.65M38.08M48.73M61.26M86.73M
EBITDA -11.42M-61.38M-66.25M-55.78M-70.54M-54.41M-7.87M-44.14M
Interest Expenses 7.71M7.71M9.32M11.06M10.05M6.55M6.34M11.12M
Shares Outstanding 0.01M24.96M33.56M34.57M41.23M54.83M68.53M91.41M
Tax Rate 0.03